Sanofi: the acquisition of Bioverativ takes shape
(CercleFinance.com) - On Friday morning Sanofi announced that the waiting period required by the Hart-Scott-Rodino Antitrust Act of 1976, which is applicable to the group's planned acquisition of Bioverativ Inc.
is now coming to an end.
As a reminder, on 7 February the French pharmaceutical giant launched a takeover bid to acquire all of Bioverativ's outstanding ordinary shares at a price of 105 dollars each, in cash, without interest and net of any mandatory withholding tax. As the waiting period provided by the HSR law has now expired, the conditions applicable to the offer imposed by the antitrust authorities have now been met.
The offer's completion, which will expire on 7 March (unless extended in accordance with the terms of the merger agreement and the US Stock Exchange regulator, SEC's applicable rules and regulations, is subject to a number of conditions, including the contribution of at least the majority of outstanding ordinary shares immediately prior to the offer's expiry, the repetition of the fiscal opinion issued upon signature and other customary conditions described in the purchase offer that Sanofi filed with the SEC on 7 February 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
is now coming to an end.
As a reminder, on 7 February the French pharmaceutical giant launched a takeover bid to acquire all of Bioverativ's outstanding ordinary shares at a price of 105 dollars each, in cash, without interest and net of any mandatory withholding tax. As the waiting period provided by the HSR law has now expired, the conditions applicable to the offer imposed by the antitrust authorities have now been met.
The offer's completion, which will expire on 7 March (unless extended in accordance with the terms of the merger agreement and the US Stock Exchange regulator, SEC's applicable rules and regulations, is subject to a number of conditions, including the contribution of at least the majority of outstanding ordinary shares immediately prior to the offer's expiry, the repetition of the fiscal opinion issued upon signature and other customary conditions described in the purchase offer that Sanofi filed with the SEC on 7 February 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.